Enter at least 3 characters
Home page > > Sustained efforts...

Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world

Date: 27/03/2020

Production and supply of medicines

Following the decree by the Italian government on March 22 calling the manufacture of all non-essential products in Italy to stop, Chiesi Group confirmed that production of all Company medicines would continue without interruption at our sites in Italy and abroad and that production would continue at the same high-quality standards. As of today, work is continuing and we are able to deliver medicines under normal production and distribution channels from all of our production plants in Italy, Brazil and France, and our global operations in research and development continue to advance.


Ugo Di Francesco, CEO Chiesi Group: “We are very pleased that we have been able to ensure the continued production and supply of our drugs to the hospitals, doctors, and patients who rely on our medicines. We continue to work with all our partners and local, national or regional bodies all over the globe to ensure we can support them to the best of our ability.”  


Alberto Chiesi, President of Chiesi Group: “In Italy we are facing what can only be described as a national emergency. As we increase our initiatives to protect our employees and patients, their safety will remain our first priority. I am deeply proud of the commitment demonstrated by all our employees in this difficult time and would like to extend my personal thanks to them all.”


For more information, read the press release from Chiesi Group or visit www.chiesi.com/en/coronavirus/


About Chiesi Group

Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&D organization is headquartered in Parma (Italy), and is integrated with R&D groups in France, the USA, the UK, and Sweden to advance Chiesi's pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people. Chiesi Group is a certified Benefit corporation. For more information, please visit www.chiesi.com